Farmas USA

osea se estoy solo ante el peligro?? vamos HZNP!!!!

Tu mirate las dos ultimas velas en semanal y evalua ...

HZNP

Creo que esto ya lo subi, pero me lo he vuelto a encontrar
la guia de solicitud de reuniones de apelacion

http://www.fda.gov/downloads/Drugs/Guidances/ucm153222.pdf

AMRN

1,99€/ +5% en pre.

A ver cómo se da la cosa hoy.

AMRN

AMRN

Las compras esas no valen pa na. Son más testimoniales que otra cosa. Están al mismo nivel que los artículos.

ONVO

Hace un año los de ONVO no se preocupaban nada de las relaciones con el inversor, pero en los últimos tiempo (con un director que nombraron si no recuerdo mal) se han vuelto muy espabilados.

Acaban de aprovechar un filling de notificación de una conferencia con inversores para rebatir los últimos artículos:

Product pipeline and revenue potential: As described previously in the company’s presentations and investor communications, including the freely available Retail Investor Conference from September 12, 2013, the company plans to launch an initial 3D liver tissue assay product in 2014, followed by a series of additional tissue assay products. Based on market research, Organovo believes that each of the product opportunities it has identified can grow into the tens of millions in annual revenue and has a $100M+ addressable market, with an overall market opportunity of $500M across all tissue products by 2018. Beyond this market opportunity, defined by sales of current cell based models, also lies the opportunity to develop products and services for the multibillion dollar animal preclinical testing market for pharmaceutical, cosmetic, and environmental industries.
Partnership model revenues: As described previously, the company will discuss its partnership model revenue opportunities, targeting $10-30M in milestone payments and 3%-7% in future royalties per opportunity. Organovo will also review its existing agreements, including its existing agreement with pre-agreed royalty and milestone payments in these ranges.
Cash burn and R&D spending: As covered in previous presentations, Organovo will review its cash position, currently consisting of approximately three years of cash on hand, and its plans to continue to grow its R&D spending in a controlled manner based on product and partnership opportunities.
Advantages of NovoGen 3D Bioprinting versus currently available technologies: Organovo will cover the advantages of its NovoGen 3D Bioprinting to achieve breakthroughs in the creation of living tissue, including its recent data from its 3D Liver product. Based on this data, which will be reviewed at the conference, the company believes its human liver model currently in development has the opportunity to redefine the category of in vitro assays as being fully human; multicellular; three dimensional in size, shape, and substance; and consistent in form and function with a native tissue sample. It also believes this set of attributes is unique and umatched by current products and technologies. Just as the creation of plastic and metal objects by 3D Printing offers significant advantages in many areas over older methods such as molding and casting, the company expects that its tissue offerings will be superior to current methods and products, none of which use any form of bioprinting today.

Analyst reports on Organovo: Organovo will review details of its prior engagement of Zacks Investment Research for independent analysis of the company starting in 2012, a contract that was terminated at Organovo’s election on September 30, 2013, as well as give guidance on future analyst coverage expectations.
Employee incentives: The Company will discuss the approval by its stockholders at the 2013 annual meeting of stockholders of 5M additional shares for future issuance under its equity incentive plan, bringing the total available to be granted in the coming years to 6M. The company filed an S-8 on August 8 to register these shareholder-approved incentive shares, which will be used to incentivize all Organovo staff in accordance with industry best practices. The company also requests that investors be certain to review its 8-K filing of October 10, 2013, in which it provided detailed, proactive guidance to investors on executive 10b5-1 plans and executive stock ownership guidelines and levels.

pre en verde, le ha sentado bien

ONVO

que penica esos 5,80 que volvio hacer HZNP. para haber dejado la orden puesta ... se me paso :(